loading...| Preferred Name |
Dexrazoxane |
|
| Synonyms |
|
|
| Definitions |
A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C1333 |
|
| Accepted_Therapeutic_Use_For |
Chemotherapy-induced cardiomyopathy |
|
| ALT_DEFINITION |
The active ingredient in a drug used to treat severe side effects caused by certain anticancer drugs. Under the brand name Totect it is used to treat the toxic effects of an anticancer drug that leaks from a vein into surrounding tissue and causes tissue damage. Under the brand name Zinecard it is used to reduce heart damage in women given doxorubicin for breast cancer that has spread. Dexrazoxane is also being studied in the treatment of cancer. It is a type of cardioprotective agent, a type of chemoprotective agent, and a type of topoisomerase inhibitor. |
|
| CAS_Registry |
24584-09-6 |
|
| CHEBI_ID |
CHEBI:50223 |
|
| Chemical_Formula |
C11H16N4O4 |
|
| code |
C1333 |
|
| Contributing_Source |
CTRP FDA PCDC |
|
| definition |
A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition. |
|
| Display_Name |
Dexrazoxane |
|
| FDA_UNII_Code |
048L81261F |
|
| Has_Salt_Form | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C186341 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C174019 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 http://purl.obolibrary.org/obo/NCIT_C186329 http://purl.obolibrary.org/obo/NCIT_C157711 |
|
| Is_PCDC_AML_Permissible_Value_For_Variable | ||
| Is_Value_For_GDC_Property | ||
| label |
Dexrazoxane |
|
| Legacy Concept Name |
Dexrazoxane |
|
| Maps_To |
Dexrazoxane |
|
| NSC Number |
169780 |
|
| Preferred_Name |
Dexrazoxane |
|
| prefixIRI |
NCIT:C1333 |
|
| prefLabel |
Dexrazoxane |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0086444 |
|
| subClassOf |